
About Bacil Pharma Ltd
Data last updated:
Bacil Pharma Ltd is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 08 May 1987 and has been in existence for over 39 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24200MH1987PLC043427. The company has 1 GST registration on record, which is no longer active. It is a listed company as per MCA records. Its shares are listed on BSE: 524516.
The company has an authorised share capital of ₹20 Cr and a paid-up capital of ₹14.35 Cr. It is led by directors including Chaitali Kalpataru Shah and Omprakash Pyarelal Sonar.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.
The net worth stands at ₹24.81 Cr (down 2.4% YoY). Total assets are valued at ₹24.81 Cr (down 3.1% YoY).
The company is associated with 1 brand: Bacil Pharma. Court records list 3 cases involving the company, including 3 filed against it. The company has 57 deals on record (57 market trades); the latest was in September 2026. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Medipex Pharmaceuticals India Private Limited with revenue of ₹66.81 Lakh.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bacilpharma.com.
Company details
Contact details
Bacil Pharma Ltd's registered office is in Mumbai, Maharashtra. Its website is bacilpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressOffice G2/G3 Samarpan Complex Next To Mirador Hotel, Link Road Opp Satam Wadi Chakala Sahar Andheri (East), Mumbai, Maharashtra, India – 400099
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Bacil Pharma Ltd, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Bacil Pharma operates one associated brand: Bacil Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of drugs | bacilpharma.com |
Financials of Bacil Pharma Ltd
FY 2025-26 filings availableBacil Pharma Ltd reported revenue of ₹- for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | (0.24) | (0.25) | (0.18) | (0.22) | (3.91) | (0.30) | (0.43) |
| Profit before tax | 1.00 | 0.41 | (0.05) | (0.11) | (3.85) | (0.23) | (0.31) |
| Net profit | 1.57 | (0.13) | (0.15) | (0.16) | (0.09) | (0.09) | (0.05) |
| EPS (₹) | 1.11 | 0.29 | (0.09) | (0.16) | (5.91) | (0.37) | (0.48) |
| Balance sheet | |||||||
| Total assets | 24.81 | 25.60 | 1.31 | 1.12 | 1.26 | 1.57 | 1.56 |
| Net worth | 24.81 | 25.43 | 1.22 | 1.10 | 1.23 | 1.39 | 1.39 |
| Total debt | 0.00 | 0.16 | 0.10 | 0.02 | 0.03 | 0.18 | 0.17 |
| Cash & bank | 0.57 | 2.86 | 0.04 | 0.03 | 0.23 | 0.10 | 0.04 |
| Net working capital | (0.83) | 2.90 | 0.03 | 0.03 | 0.23 | (2.36) | (2.45) |
| Cash flow | |||||||
| Cash from operations | 0.71 | 0.40 | 0.00 | (0.15) | (4.01) | (0.40) | (0.38) |
| Cash from investing | (2.38) | 0.34 | 0.08 | (0.12) | 3.81 | 0.53 | 0.39 |
| Cash from financing | (0.62) | 2.08 | (0.06) | 0.06 | 0.33 | (0.07) | (0.06) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.09 | 0.09 | 0.11 | 0.06 | 0.05 | 1.00 | 0.09 | 0.00 |
| Total expenses | 0.06 | 0.02 | 0.07 | 0.03 | 0.04 | 0.11 | 0.07 | 0.06 |
| EBITDA | (0.06) | (0.02) | (0.07) | (0.03) | (0.04) | (0.11) | (0.07) | (0.06) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.03 | 0.07 | 0.04 | 0.03 | 0.01 | 0.89 | 0.02 | (0.06) |
| Tax | 0.04 | 0.08 | (0.58) | 0.00 | 0.00 | 0.22 | 0.00 | 0.00 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.09 | 0.09 | 0.11 | 0.06 | 0.05 | 1.00 | 0.09 | 0.00 |
| Total expenses | 0.06 | 0.02 | 0.07 | 0.03 | 0.04 | 0.11 | 0.07 | 0.06 |
| EBITDA | (0.06) | (0.02) | (0.07) | (0.03) | (0.04) | (0.11) | (0.07) | (0.06) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.03 | 0.07 | 0.04 | 0.03 | 0.01 | 0.89 | 0.02 | (0.06) |
| Tax | 0.04 | 0.08 | (0.58) | 0.00 | 0.00 | 0.22 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 1.24 | 0.66 | 0.13 | 0.11 | 0.06 | 0.07 | 0.14 |
| Total expenses | 0.24 | 0.25 | 0.18 | 0.22 | 3.91 | 0.30 | 0.43 |
| Employee cost | 0.05 | 0.14 | 0.10 | 0.09 | 0.06 | 0.05 | 0.09 |
| EBITDA | (0.24) | (0.25) | (0.18) | (0.22) | (3.91) | (0.30) | (0.43) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Profit before tax | 1.00 | 0.41 | (0.05) | (0.11) | (3.85) | (0.23) | (0.31) |
| Tax | (0.57) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | 1.57 | (0.13) | (0.15) | (0.16) | (0.09) | (0.09) | (0.05) |
| EPS (₹) | 1.11 | 0.29 | (0.09) | (0.16) | (5.91) | (0.37) | (0.48) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 13.97 | 13.97 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 |
| Reserves & surplus | 10.84 | 11.46 | (5.31) | (5.43) | (5.30) | (5.14) | (5.14) |
| Shareholders' funds (net worth) | 24.81 | 25.43 | 1.22 | 1.10 | 1.23 | 1.39 | 1.39 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.18 | 0.17 |
| Unsecured loans | 0.00 | 0.16 | 0.10 | 0.02 | 0.00 | 0.00 | 0.00 |
| Total debt | 0.00 | 0.16 | 0.10 | 0.02 | 0.03 | 0.18 | 0.17 |
| Total liabilities | 24.81 | 25.60 | 1.31 | 1.12 | 1.26 | 1.57 | 1.56 |
| Assets | |||||||
| Gross block | 0.00 | 0.00 | 0.06 | 0.06 | 0.06 | 2.56 | 2.56 |
| Net block | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 2.52 | 2.52 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 24.24 | 21.36 | 0.61 | 0.43 | 0.31 | 0.37 | 0.43 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sundry debtors | 1.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank balances | 0.57 | 2.86 | 0.04 | 0.03 | 0.23 | 0.10 | 0.04 |
| Loans & advances | 0.00 | 0.05 | 0.01 | 0.01 | 0.01 | 0.06 | 0.06 |
| Total current assets | 1.75 | 2.91 | 0.05 | 0.04 | 0.24 | 0.16 | 0.10 |
| Total current liabilities | 2.58 | 0.01 | 0.02 | 0.01 | 0.01 | 2.52 | 2.55 |
| Net working capital | (0.83) | 2.90 | 0.03 | 0.03 | 0.23 | (2.36) | (2.45) |
| Total assets | 24.81 | 25.60 | 1.31 | 1.12 | 1.26 | 1.57 | 1.56 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.86 | 0.04 | 0.03 | 0.23 | 0.10 | 0.04 | 0.09 |
| Net cash from operating activities | 0.71 | 0.40 | 0.00 | (0.15) | (4.01) | (0.40) | (0.38) |
| Net cash from investing activities | (2.38) | 0.34 | 0.08 | (0.12) | 3.81 | 0.53 | 0.39 |
| Net cash from financing activities | (0.62) | 2.08 | (0.06) | 0.06 | 0.33 | (0.07) | (0.06) |
| Net change in cash | (2.29) | 2.82 | 0.01 | (0.20) | 0.13 | 0.06 | (0.05) |
| Closing cash | 0.57 | 2.86 | 0.04 | 0.03 | 0.23 | 0.10 | 0.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| EBITDA growth | +4.0% | -38.9% | +18.2% | +94.4% | -1203.3% | +30.2% | - |
| PBT growth | +143.9% | +9998.0% | +54.6% | +97.1% | -1573.9% | +25.8% | +13.9% |
| Net income growth | +1307.7% | +13.3% | +6.3% | -77.8% | 0.0% | -80.0% | - |
| EBITDA CAGR (3Y) | +2.9% | -60.0% | -15.7% | -20.0% | +107.1% | -57.8% | +36.3% |
| Profitability & leverage | |||||||
| Return on capital employed | +3.9% | -1.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Return on net worth | +6.2% | -1.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt / equity | 0.00 | 0.01 | 0.05 | 0.02 | 0.08 | 0.13 | 0.08 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.27 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debtors turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS (₹) | 1.11 | 0.29 | (0.09) | (0.16) | (5.91) | (0.37) | (0.48) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 17.76 | 18.20 | 1.86 | 1.68 | 1.88 | 2.13 | 2.12 |
To see the full year-wise statements and ratios of Bacil Pharma Ltd, buy the company report.
Board of directors of Bacil Pharma Ltd
Bacil Pharma has 3 current directors and 17 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Chaitali Kalpataru Shah Also directs: Bacil Research & Development Private Limited | Additional Director | 16 Jul 2025 | 1 Years 4 Months | Current |
| Omprakash Pyarelal Sonar Also directs: Goodspark Trading Private Limited | Additional Director | 30 Jun 2026 | 0 Years 4 Months | Current |
| Vivek Mukesh Yadav | Additional Director | 30 Jun 2026 | 0 Years 4 Months | Current |
Peer comparison
Bacil Pharma Ltd is compared with the 10 companies closest to it by revenue in the Pharma industry (Formulations), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Medipex Pharmaceuticals India Private Limited | ₹66.81 Lakh (FY 2025) | 53175.0% | Mumbai, Maharashtra, India | |||
| Ferico Pharma (India) Pvt Ltd | ₹66.61 Lakh (FY 2025) | 6.0% | Navi Mumbai, Maharashtra, India | |||
| Ruso Pharma Private Limited | ₹66.5 Lakh (FY 2025) | -5.0% | Navi Mumbai, Maharashtra, India | |||
| Membrane Pharma India Private Limited | ₹66.29 Lakh (FY 2025) | 44.0% | Gurugram, Haryana, India | |||
| Greenenvy Healthcare Private Limited | ₹66.19 Lakh (FY 2025) | -71.0% | Mangalore, Karnataka, India | |||
| G and B Pharmaceuticals Private Limited | ₹65.84 Lakh (FY 2023) | 294.0% | Jagadhri, Haryana, India | |||
| Calsita Futuristic Private Limited | ₹65.57 Lakh (FY 2025) | 91.0% | Vadodara, Gujarat, India | |||
| Nunchi Pharma Private Limited | ₹65.56 Lakh (FY 2025) | 3.0% | Delhi, India | |||
| Kancare Pharmaceuticals Private Limited | ₹65.29 Lakh (FY 2023) | 1596.0% | Roorkee, Uttarakhand, India | |||
| Hindustan Pharmatech Private Limited | ₹65.21 Lakh (FY 2025) | -34.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Bacil Pharma Ltd, buy the company report.
Auditor
Bacil Pharma Ltd is audited by Laxmikant Kabra & Co. LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Laxmikant Kabra & Co. LLP | FY 2023 | 117183W |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 0.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 100.00%.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 0.00% | 0.10% | 0.10% | 0.20% |
| Public | 100.00% | 99.90% | 99.90% | 99.80% |
Deals & funding
Bacil Pharma Ltd has 57 deals on record (57 market trades); the latest was in September 2026.
Deals on record (5 of 57)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2026 | Market trade | ₹34.8 Lakh | Buyer: Shrynax Trading Private Limited |
| Aug 2026 | Market trade | ₹9.9 Lakh | Buyer: Brenley Engineers Private Limited |
| Aug 2026 | Market trade | ₹1.17 Cr | Buyer: Jr Seamless Private Limited , 3 individuals Seller: MNM Stock Broking Private Limited , 3 individuals |
| Jul 2026 | Market trade | ₹27.6 Lakh | Buyer: Spextra Multibiz Private Limited Seller: Spextra Multibiz Private Limited |
| Jul 2026 | Market trade | ₹1.16 Cr | Buyer: MNM Stock Broking Private Limited , Amnesti Multiservices Private Limited , Silver Stone Capital Seller: Amnesti Multiservices Private Limited , an individual |
To see the full deal history of Bacil Pharma Ltd, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Bacil Pharma Ltd has 3 court cases on record: 3 filed against it. All cases are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 3 | 3 | 0 |
Cases on record (3 of 3)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai CMM Courts, Maharashtra | Court case (SUMMONS CASES SS) | Filed against the company by an individual | Disposed |
| District court, Mumbai CMM Courts, Maharashtra | Civil suit | Filed against the company by an individual | Disposed |
| District court, Mumbai City Civil Court, Maharashtra | Civil suit | Filed against the company by Clea Advertising and Marketing Ltd | Disposed |
To see the full case history of Bacil Pharma Ltd, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Bacil Pharma Ltd; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Bacil Pharma has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.
To see the full GST registrations and return filing status of Bacil Pharma Ltd, buy the company report.
Recent activity
Bacil Pharma Ltd has 27 board changes on record since 1990: 16 appointments and 11 cessations. The latest: Omprakash Pyarelal Sonar was appointed as Additional Director on 30 Jun 2026.
18 earlier events are in the company report.
Frequently asked questions
Bacil Pharma is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 08 May 1987 (39+ years old) and is registered under CIN L24200MH1987PLC043427. Listed on BSE: 524516.
Bacil Pharma has 3 current directors:
- Chaitali Kalpataru Shah - Additional Director
- Omprakash Pyarelal Sonar - Additional Director
- Vivek Mukesh Yadav - Additional Director
The latest financial statements of Bacil Pharma on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.
No. Bacil Pharma has 1 GST registration on record and it is cancelled or inactive.
The CIN (Corporate Identification Number) of Bacil Pharma is L24200MH1987PLC043427. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Bacil Pharma is a listed company as per MCA records. Its shares are listed on BSE (code: 524516).
Bacil Pharma has 3 court cases on record: 3 filed against it.
Bacil Pharma was incorporated on 08 May 1987, making it 39+ years old. It is registered with the Registrar of Companies, Mumbai.
Bacil Pharma has 57 deals on record (57 market trades); the latest was in September 2026.
The peers of Bacil Pharma by revenue are Medipex Pharmaceuticals India Private Limited, Ferico Pharma (India) Pvt Ltd, Ruso Pharma Private Limited, Membrane Pharma India Private Limited, Greenenvy Healthcare Private Limited and 5 more, all in the Pharma industry (Formulations).
Omprakash Pyarelal Sonar was appointed as Additional Director on 30 Jun 2026. Vivek Mukesh Yadav was appointed as Additional Director on 30 Jun 2026. Ganpat Dhondu Salekar ceased to be Manager on 12 Aug 2025. Bacil Pharma has 27 board changes on record in total.

